Fas (Apo-1/CD95) is a cell-surface receptor involved in cell death signaling. The key role of the Fas system in negative growth regulation has been studied mostly within the immune system, and somatic mutations of Fas gene in cancer patients have been described solely in lymphoid-lineage malignancies. However, many nonlymphoid tumor cells have been found to be resistant to Fas-mediated apoptosis, which suggests that Fas mutations, one of the possible mechanisms for Fas-resistance, may be involved in the pathogenesis of non-lymphoid malignancies as well. In this study, we have analysed the entire coding region and all splice sites of the Fas gene for the detection of the gene mutations in 65 human nonsmall cell lung cancers by polymerase chain reaction, single strand conformation polymorphism and DNA sequencing. Overall, ®ve tumors (7.7%) were found to have the Fas mutations, which were all missense mutations. Four of the ®ve mutations identi®ed were located in the cytoplasmic region (death domain) known to be involved in the transduction of an apoptotic signal and one mutation was located in the transmembrane domain. This is the ®rst report on the Fas gene mutations in non-lymphoid malignancies, and the data presented here suggests that alterations of the Fas gene might lead to the loss of its apoptotic function and contribute to the pathogenesis of some human lung cancers.
Introduction
The Fas-Fas ligand (FasL) system has been recognized as a major pathway for the induction of apoptosis in cells and tissues (Nagata, 1997) . Fas is a member of the death receptor subfamily of the tumor necrosis factor receptor superfamily. Fas has three cystein-rich extracellular domains and an intracellular death domain essential for signaling (Itoh and Nagata, 1993; Trauth et al., 1989; Yonehara et al., 1989) . Ligation of Fas by either agonistic antibody or by its natural ligand transmits a`death signal' to the target cells, potentially triggering apoptosis (Itoh et al., 1991; LeithaÈ user et al., 1993; Suda et al., 1993; Suda and Nagata, 1994; Trauth et al., 1989; Yonehara et al., 1989) .
Fas is widely expressed in normal and neoplastic cells (LeithaÈ user et al., 1993) , but the expression of this protein does not necessarily predict susceptibility to killing (Beltinger et al., 1998; Nambu et al., 1998; Natoli et al., 1995; Owen-Schaub et al., 1994) . This can re¯ect the presence of inhibiting mechanisms of Fasmediated apoptosis. Fas-mediated apoptosis can be blocked by several mechanisms, including the production of soluble Fas (Natoli et al., 1995) , the lack of cellsurface Fas expression (Bennett et al., 1998; Hughes et al., 1997) , the overexpression of inhibitory proteins in signal transduction pathways such as Fas associated phosphatase-1 (Sato et al., 1995) and FLIP (Irmler et al., 1997) , and the mutation of the primary structure of Fas (Beltinger et al., 1998; Bettinardi et al., 1997; Drappa et al., 1996; Grùnbñk et al., 1998; Landowsky et al., 1997; Rieux-Laucat et al., 1995; Tamiya et al., 1998; Watanabe-Fukunaga et al., 1992) .
The consequences of the Fas gene mutations have been well demonstrated in germline mutation models of this gene (Bettinardi et al., 1997; Drapa et al., 1996; Rieux-Laucat et al., 1995; Watanabe-Fukunaga et al., 1992) . Mice bearing the Fas gene mutation (lpr) have an abnormality of mature T-cell deletion in the peripheral tissues, resulting in lymphadenopathy, splenomegaly and systemic autoimmune disease (Watanabe-Fukunaga et al., 1992) . Germline mutations of the Fas gene in human also result in autoimmune lymphoproliferative syndrome (ALPS), which is characterized by an increase in doublenegative T-cells and profound lymphadenopathy (Bettinardi et al., 1997; Drappa et al., 1996; RieuxLaucat et al., 1995) , as observed in lpr mice. Most of the Fas mutations in ALPS, of which the majority were point mutations in the death domain, were heterozygous and showed a dominant negative phenotype (Bettinardi et al., 1997; Drappa et al., 1996; RieuxLaucat et al., 1995) . Interestingly, the lpr mice have been reported to have spontaneous development of plasmacytoid tumors (Davidson et al., 1998) and some ALPS patients have been reported to have malignancies (Bettinardi et al., 1997; Drappa et al., 1996) , including multiple tumor development in one patient (Drappa et al., 1996) . Although it is not clear if the tumors that occurred in ALPS patients arose as a result of Fas mutations, it is conceivable that Fas mutation might have in¯uences on tumor development in these patients.
The key role of the Fas system in negative growth regulation has been studied mostly within the immune system (Nagata, 1997) and the mutations of Fas gene in cancer patients have been described solely in lymphoid-lineage malignancies, including multiple myelomas (Landowsky et al., 1997) , adult T-cell leukemias (Tamiya et al., 1998) , childhood T-cell lymphoblastic leukemias (Beltinger et al., 1998) and non-Hodgkin's lymphomas (Grùnbñk et al., 1998) . Some of these mutations were associated with decreased Fas-mediated apoptosis by the agonistic antibody for Fas (Beltinger et al., 1998; Tamiya et al., 1998) . In these lymphoid-lineage malignancies, therefore, resistance against Fas-mediated apoptosis may lead to a longer survival of aected tumor cells and might contribute to tumorigenesis.
There is mounting evidence that disruption of Fas system frequently occurs in non-lymphoid malignancies as well (Nambu et al., 1998; Natoli et al., 1995; OwenSchaub et al., 1994; Ungefroren et al., 1998) . To date, however, somatic mutations of Fas gene, one of the possible mechanisms that mediates the disruption of Fas system, have not yet been reported in nonlymphoid malignancies including non-small cell lung cancer (NSCLC). Previous LOH study has suggested that loss of one or more tumor suppressor genes at chromosome 10q22-26 may be involved in the development of NSCLC (Petersen et al., 1998) . And, one of the candidate genes is Fas which is located at chromosome 10q24.1. In the present study, in order to characterize the potential apoptosis-resistant pathway of Fas system in human NSCLC, we analysed a series of 65 NSCLCs for the detection of somatic mutations of the Fas gene. 
Results
Through microdissection technique, we successfully procured tumor cells from formalin-®xed, paranembedded tissue sections, as shown in Figure 1A and B. This microdissection technique used in this study has been proven to be precise and eective for procurement of tumor cells without normal cell contamination (Lee et al., 1998a) . Genomic DNA was isolated from 65 NSCLCs and analysed for mutations and allelic deletions of the Fas gene by PCR (polymerase chain reaction) ± SSCP (single strand conformation polymorphism) using primer sets covering the entire coding region and parts of the promoter region (Table 1) .
Fas gene mutations SSCP analysis identi®ed six aberrant bands, including ®ve in exon 9 and one in exon 6 (Figure 2A and B). Sequencing analysis of these aberrant bands showed ®ve missense mutations and one silent mutation (Table  2 and Figure 2C ), and none of these mutations were present in normal DNA from the same patients ( Figure  2A and B), indicating the aberrant bands did not originate from germline alterations. Of the ®ve missense mutations, four mutations (cases 1, 2, 3 and 4) were detected in exon 9, which encodes the death domain of Fas (Itoh and Nagata, 1993) . These mutations aect codons 250, 251, 255 and 269 of Fas, and would result in amino acid substitutions (Table 2) . A remaining missense mutation involved codon 162 in exon 6, which encodes the transmembrane region of membrane-bound Fas (Itoh and Nagata, 1993) . As for the relationship between histologic type and Fas gene mutations, four of ®ve missense mutations were detected in squamous cell carcinoma, but it was not statistically signi®cant (Fisher's exact test, two tails, P40.05). The detection of Fas gene mutations were reproducible through triplicate experiments including tissue microdissection, PCR, SSCP and sequencing analysis, ensuring the speci®city of the results.
Allelic status
Because missense mutations in the death domain of Fas in patients with ALPS have been suggested to aect receptor function in a dominant-negative fashion (Rieux-Laucat et al., 1995) , we examined the allelic status of Fas in tumors carrying missense mutations. Since it has been known that four polymorphisms at positions 71377 (promoter region), 7670 (promoter region), 416 (exon 3) and 836 (exon 7) are located in Fas gene (Fiucci and Ruberti 1994; Huang et al., 1997) , SSCP analysis at these polymorphic sites was used for the detection of LOH as well as for mutations. In NSCLCs analysed, heterozygosity rates of the two polymorphic markers (3A and 7) in exons 3 and 7 were too low for LOH study, whereas 39 out of 65 (60%) cases showed heterozygosity with one or both of the two polymorphic markers (PA and PB) in the promoter region of the Fas gene. Overall, 41 out of 65 cases (63%) were informative for at least one of the four polymorphic markers, and 12 out of 41 (29%) informative cases showed LOH with one or more markers. Seven of 24 (29%), seven of 31 (23%), none of one (0%) and none of one (0%) informative cases showed LOH with the polymorphic markers PA, PB, 3A and 7, respectively ( Figure 2D and Table 2 ). Among the ®ve cases with the mutations, two patients (cases 1 and 2) were heterozygous for one polymorphism at position 7670, allowing the evaluation of allelic loss in their tumors by SSCP. These two informative cases showed equal distribution of the two alleles, indicating retention of the wild-type allele in the tumor cells ( Figure 2D, left) .
Interestingly, however, in two out of the ®ve mutations (cases 1 and 3) SSCP patterns at the mutation sites (exon 9) showed only aberrant bands of mutant allele without those of the wild-type allele ( Figure 2B ), and sequencing analysis also revealed only mutation sequences without wild-type ones, indicating either homozygous mutation or hemizygous mutation with allelic loss ( Figure 2C ). In contrast, the other three cases (cases 2, 4 and 5) showed that the bands of wild type allele were noted together with aberrant bands of mutant allele (Figure 2A ). The bands of wild-type alleles in the latter three cases could result from normal tissue contamination, but, we used micrometrically precise, microdissection technique using micromanipulator (Figure 1) (Lee et al., 1998a) , and all LOH findings in the present study showed almost complete absence of signals in deleted alleles of tumor DNA (Figure  2d ), indicating that the microdissected tumor samples are nearly devoid of normal tissue contamination. Therefore, we interpreted the latter three cases as having hemizygous mutation without allelic loss. Twelve of 41 (29%) informative cases in which no Fas mutations had been detected showed evidence of allelic loss (Table 2) . Therefore, although SSCP analysis at the polymorphic sites did not prove direct evidence on the second allele status in the mutation cases, the SSCP patterns at mutation sites and sequencing analysis suggest that the second allele had been also altered in two out of ®ve patients carrying missense mutations.
Expression of Fas and FasL
We demonstrated Fas and FasL expressions in NSCLC by immunohistochemistry. The tumors showed immunoreactivity for Fas in 52 of 65 cases (80%). As for the relationship between the Fas-expression and histologic type, Fas was expressed in 24 (80%) squamous cell carcinomas, 20 (83%) adenocarcinomas, and eight (73%) bronchioloalveolar carcinomas. In agreement with the previous report (Niehans et al., 1997) , FasL was expressed in all NSCLC analysed (100%). Fas and FasL immunostainings, when present, were cytoplasmic and along the cell membranes; nuclei were clearly negative ( Figure 3 ). All NSCLC with the Fas gene mutations coexpressed Fas and FasL (Table 2) . Immunoreactivity (Fas and FasL) and the histologic types of the cases with Fas mutations or allelic deletions are summarized in Table 2 .
Discussion
The aim of this study was to detect the Fas gene alterations, one of the possible mechanisms that may mediate the Fas-resistance in NSCLC in vivo. Although we do not actually know whether NSCLC is resistant to Fas-mediated apoptosis in vivo, there have been some data that support the idea that NSCLC may be resistant to Fas-mediated apoptosis. For example, some pulmonary adenocarcinoma cell lines were reported to have resistance to Fas-mediated apoptosis, despite expressing Fas (Nambu et al., 1998) . In addition, 80% of the human NSCLC analysed in the present study, expressed both Fas and FasL, suggesting that these tumors may be resistant to Fas-mediated apoptosis in vivo to escape autocrine suicide.
Previous identi®cation of LOH at chromosome 10q22-26 in NSCLC has suggested the presence of putative tumor suppressor genes in this area (Petersen et al., 1998) . Recently, researchers have examined PTEN/MMAC1, a gene mapping to 10q23.3 and encoding a tumor suppressor commonly altered in many types of human cancer Teng et al., 1997) , but found that this gene is rarely mutated in primary NSCLCs (Forgacs et al., 1998 Yokomizo et al., 1998) . In the present study, we have systematically examined the Fas gene on 10q24.1 and documented somatic mutations in ®ve of 65 NSCLCs. Therefore, the presence of Fas gene mutations suggested that this gene is likely to be one of the candidate tumor suppressor genes relevant to NSCLC.
Although functional studies have not yet been performed, part of the mutations identi®ed in the present study is likely to disrupt or alter the normal function of Fas. To date, loss-of-function mutations of Fas, identi®ed in lpr mice (Watanabe-Fukugana et al., 1992) , ALPS patients (Bettinardi et al., 1997; Drappa et al., 1996; Rieux-Laucat et al., 1995) , and some lymphoid malignancies (Beltinger et al., 1998; Grùn-bñk et al., 1998; Landowsky et al., 1997; Tamiya et al., 1998) , have been identi®ed in the promoter, exon 2, exon 3, exon 4 and exon 6, exon 7, exon 8 and exon 9. However, most of the mutations have been detected in exon 9 by which death domain is encoded. Death domain is evolutionarily highly conserved and is shown to be necessary and sucient for the transduction of an apoptotic signal (Itoh et al., 1991) . In the current study, four of ®ve Fas mutations were identi®ed in this conserved area, suggesting that the mutations might disrupt death signaling. In the current study, one mutation (case 6) was identi®ed in exon 6 which encodes the transmembrane domain of the Fas protein (Itoh et al., 1991) , but the functional signi®cance of this mutation remains unknown at this stage.
In multiple myeloma, Landowski et al. (1997) identi®ed an identical point mutation in two different patients, which generate an amino acid substitution at 253. Also, mutations of codon 248 and 256 of Fas were identi®ed in non-Hodgkin's lymphomas (Grùn-bñck et al., 1998). Furthermore, two ALPS patients were reported to have 2-bp deletion which generates an unrelated amino acid sequence beginning at residue 254 (Rieux-Laucat et al., 1995) . Of the 5 Fas gene mutations detected in the present study, three mutations generated amino acid substitution at residues 250, 251 and 255, which are close to the Fas mutations described above, indicating that this area may be a potential hot spot in the Fas coding sequence.
Most of the patients with ALPS carry a heterozygous mutation in the Fas gene (Bettinardi et al., 1997; Drappa et al., 1996; Rieux-Laucat et al., 1995) . In the ALPS, the aected Fas protein seemed to work in a dominant-negative fashion, and T-lymphocytes from these patients did not die upon activation (Bettinardi et al., 1997; Drappa et al., 1996; RieuxLaucat et al., 1995) . Upon binding with FasL or antiFas antibody, Fas proteins are believed to trimerize each other and then transduce the death signal (Nagata, 1997) . In our study, of the ®ve cases with missense mutations, three seemed to be hemizygous mutations without allelic deletion (Figure 2A ). Therefore, in these cases it is possible that the hemizygously mutated Fas protein(s) may bind with other normal Fas protein(s), construct a structurally abnormal Fastrimer and block the death signal transduction. In contrast, two cases (cases 1 and 3) with missense mutations showed alterations of both alleles ( Figure  2B ), indicating potential bi-allelic inactivation of the Fas gene.
Several lines of evidence suggest that the loss of Fas function can enhance lymphoid tumor development. Lymphomatogenesis driven by the Em-myc transgene was shown to be markedly accelerated in lpr mice compared to wild-type mice, con®rming a causal, rather than correlative, role for Fas loss in tumor development (ZoÈ rnig et al., 1995) . Spontaneous development of B-cell lymphoid tumors in lpr mice also indicated that Fas gene mutation plays a key role in the development of B-cell transformation (Davidson et al., 1998) . Moreover, Fas gene mutations in human cancer patients have been found exclusively in lymhpoid malignancies. These are well correlated with the facts that ALPS patients and lpr mice have shown phenotypical abnormalities only in lymphoid system (Bettinardi et al., 1997; Drappa et al., 1996; RieuxLaucat et al., 1995; Watanabe-Fukugana et al., 1992) . However, we were able to ®nd Fas gene mutations in NSCLC, one of non-lymphoid malignancies, which can extend the concept of loss of Fas function to the pathogenesis of non-lymphoid malignancies and it is possible that Fas gene mutations may occur widely in non-lymphoid malignancies as well. Clearly, therefore, studies are now needed that attempt to ®nd the potential Fas gene mutations in other non-lymphoid malignancies.
Materials and methods

Tissue samples
Formalin-®xed and paran-embedded archival tissues of human NSCLC were obtained from 65 surgically treated patients. Histopathological examination of these NSCLCs revealed that the tumors consisted of 30 squamous cell carcinomas, 24 adenocarcinomas and 11 bronchioloalveolar carcinomas.
Microdissection and DNA extraction
Malignant cells were selectively procured from H & E-stained slides without any normal cell contamination using a 30G1/2 hypodermic needle (Becton Dickinson, Franklin Lakes, NJ, USA) axed to a micromanipulator, as described previously (Lee et al., 1998a) . We also microdissected in®ltrating lymphocytes for corresponding normal DNA from the same slide in all cases.
DNA extraction was performed by a modi®ed single-step DNA extraction method, as described previously (Lee et al., 1998a) .
SSCP analysis for mutation and LOH
Genomic DNA each from normal lymphocytes or tumor cells was ampli®ed with primer pairs covering the entire coding region and parts of the promoter region of Fas gene (Table  1) . Oligonucleotide primers were designed with the program Oligo (National Biosciences, Plymouth, MN, USA) using sequences obtained from Genbank (accession #M67454). Each PCR reaction was performed under standard conditions in a 10 ml reaction mixture containing 1 ml of template DNA, 0.5 mM of each primer, 0.2 mM of each deoxynucleotide triphosphate, 1.5 mM MgCl 2 , 0.4 unit of Taq polymerase, 0.5 mCi of [ 32 P]dCTP (Amersham, Buckinghamshire, UK), and 1 ml of 106buer. The reaction mixture was denatured for 1 min at 948C and incubated for 40 cycles (denaturing for 40 s at 948C, annealing for 40 s at variable temperatures as described in Table 1 , and extending for 40 s at 728C). Final extension was continued for 5 min at 728C. After amplification, PCR products were denatured 5 min at 958C at a 1 : 1 dilution of sample buer containing 98% formamide/ 5 mmol/l NaOH and were loaded onto a SSCP gel (FMC Mutation Detection Enhancement system; Intermountain Scienti®c, Kaysville, UT, USA) with 10% glycerol. Samples were electrophoresed at 8 W at room temperature overnight. After electrophoresis, the gels were transferred to 3-mm Whatman paper and dried, and autoradiography was performed with Kodak X-OMAT ®lm (Eastman Kodak, Rochester, NY, USA). For the detection of mutations, DNAs showing mobility shifts were cut out from the dried gel, and re-ampli®ed for 35 cycles using the same primer set. Sequencing of the PCR products was carried out using the cyclic sequencing kit (Perkin-Elmer, CA, USA) according to the manufacturer's recommendation.
The polymorphic sites at positions 71377 (promoter region), 7670 (promoter region), 416 (exon 3) and 836 (exon 7) were examined for LOH studies by using primer sets PA, PB, 3A and 7, respectively. The PCR and SSCP conditions were the same with the condition described above. Complete or nearly complete absence of one allele in tumor DNA of informative cases, as de®ned by direct visualization, was considered as LOH.
Immunohistochemistry
Antibody for human Fas (C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and antibody for human FasL (N-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used to detect Fas and FasL on tissue sections. Immunohistochemical procedures were performed as described previously (Lee et al., 1998b) . Tumors were interpreted as positive for Fas and FasL by immunohistochemistry when at least weak to moderate cytoplasmic staining was seen in greater than 30% of the neoplastic cells. The immunostaining with each antibody was judged to be antibody-speci®c by several criteria, including (a) use of normal rabbit serum at the same dilution produced no consistent immunostaining of any cells; (b) intensity of the signal diminished as the dilution of antibodies was increased; and (c) preincubating each antibody with each blocking peptide abrogated the positive immunostaining. The results were reviewed independently by three pathologists.
